IV-001 Gianluca Selvaggio
Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children
Thursday 15:00-16:30 |
IV-002 Carlos Serra Traynor
DeepCIM: Prediction of myelosuppressive anti-cancer molecules using drug-target interaction datasets
Thursday 15:00-16:30 |
IV-003 Alejandro Serrano Alcaide
Relationship between tumor growth and Treg activation status to optimize a previously published Immune oncology framework
Thursday 15:00-16:30 |
IV-004 Jérémy Seurat
Macrophage-induced reduction of bacteriophage density limits the efficacy of pulmonary phage therapy
Thursday 15:00-16:30 |
IV-005 Chaozhuang Shen
A Physiologically-Based Quantitative Systems Pharmacology (PB-QSP) Model for Individualized Prediction of Treatment Outcomes with Alogliptin in the Renal Impairment Population
Thursday 15:00-16:30 |
IV-006 Valerie Sia
Aging-related CYP3A functional changes: Novel findings from a model-based assessment of real-world pharmacokinetic study in Chinese older inpatients
Thursday 15:00-16:30 |
IV-007 Anastasios Siokis
In-silico clinical trials in virtual asthma patients powered by QSP accelerated the development of lunsekimig
Thursday 15:00-16:30 |
IV-008 Lucia Siovitz
Characterizing the Longitudinal Exposure-Response Relationship of Upadacitinib Efficacy in Vitiligo: Insights from Analysis of Phase 2 Clinical Data
Thursday 15:00-16:30 |
IV-010 Erik Sjögren
Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology framework
Thursday 15:00-16:30 |
IV-011 Victor Sokolov
Quantitative Systems Pharmacology Model of Type 1 IFN-mediated Inflammation in Systemic Lupus Erythematosus
Thursday 15:00-16:30 |
IV-012 Pooneh Soltantabar
Elranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma: Insights from MagnetisMM Studies
Thursday 15:00-16:30 |
IV-013 Meemansa Sood
Lutathera dose determination and justification in adolescents via population PK and dosimetry modeling and simulation
Thursday 15:00-16:30 |
IV-014 Tomás Sou
Population PK/PD modelling to evaluate the effect of siremadlin and disease progression on platelet dynamics in haematological malignancies
Thursday 15:00-16:30 |
IV-015 Angelica Squarzoni
Pharmacodynamic Drug-Drug Interaction Between Oxaliplatin and HDAC Inhibitors in Colorectal Cancer Cell Lines
Thursday 15:00-16:30 |
IV-016 Felix Stader
Physiologically based pharmacokinetic modelling to predict the concentration-time profile of an antibody-drug conjugate and hepatic and renal impairment.
Thursday 15:00-16:30 |
IV-017 Britta Steffens
Pharmacometric analysis to explore moxidectin treatment with and without albendazole in Trichuris trichiura-infected adolescents
Thursday 15:00-16:30 |
IV-019 Marie Steinacker
Combining biological knowledge and machine learning for predicting dynamics of haematotoxcity after chemotherapy: a comparative analysis
Thursday 15:00-16:30 |
IV-020 Oleg Stepanov
Utilizing the AZD7442 Model for Accelerated New Drug Development: Pharmacokinetic Insights Across Infectious Disease Prevention and Passive Immunization
Thursday 15:00-16:30 |
IV-021 Ida Storgaard
Population pharmacokinetic-pharmacodynamic model of subcutaneous bupivacaine in a novel extended-release microparticle formulation
Thursday 15:00-16:30 |
IV-022 Hong Su
How should target-mediated drug disposition model be used for predicting receptor occupancy?
Thursday 15:00-16:30 |
IV-023 ming sun
Bayesian PBPK modeling for acyclovir dose optimization for treating viral encephalitis
Thursday 15:00-16:30 |
IV-024 Bae Sungyeun
Population pharmacokinetics of intravenous MIT-001 in healthy subjects and patients
Thursday 15:00-16:30 |
IV-025 Mikael Sunnåker
A Generative Pre-trained Transformer for Time-Course and Dose-Response Predictions
Thursday 15:00-16:30 |
IV-026 Budi Octasari Susanto
An integrative translational framework for in vitro modelling for macozinone to support prediction of early human anti-tubercular efficacy
Thursday 15:00-16:30 |
IV-027 Jérémie Tachet
Population pharmacokinetic modelling of oral ruxolitinib: a real-world prospective observational study
Thursday 15:00-16:30 |
IV-028 Sung Taewook
Optimizing IMC-001 Dosage Regimens Using Target Mediated Drug Disposition Model: Enhancing Therapeutic Efficacy and Safety in Cancer Treatment
Thursday 15:00-16:30 |
IV-029 Zhiyuan Tan
Model-informed pazopanib dose optimization in real-world cancer patients
Thursday 15:00-16:30 |
IV-030 Sebastian Tandar
Population-level treatment optimization using a multi-objective optimization strategy
Thursday 15:00-16:30 |
IV-031 Olga Teplytska
Machine Learning algorithms for concentration prediction in anticancer drug therapy: Towards a method for individual dose adjustment
Thursday 15:00-16:30 |
IV-032 David Ternant
Unveiling a “predator/prey” interplay of anti-CD19 CAR T-Cells and their targets in Relapsed/refractory DLBCL patients
Thursday 15:00-16:30 |
IV-033 Adrien Tessier
Joint Modeling Of Longitudinal Circulating Tumor DNA And Survival In Metastatic Colorectal Cancer: A Promise Of Early Prediction Of Response In Oncology?
Thursday 15:00-16:30 |
IV-034 Florencia Tettamanti
Predicting Progression Free Survival from Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL)
Thursday 15:00-16:30 |
IV-035 Donato Teutonico
Estimation of population parameter values and variability coupling non-linear mixed-effects modeling (based on SAEM algorithm) with a whole-body PBPK model
Thursday 15:00-16:30 |
IV-036 Hoai-Thu Thai
A joint modeling approach leveraging intravenous data to support dose selection of subcutaneous isatuximab in combination with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma
Thursday 15:00-16:30 |
IV-037 Veena Thomas
Utility of Physiologically-based Pharmacokinetic Model to Predict Inter-Antibody Variability in Monoclonal Antibody Pharmacokinetics
Thursday 15:00-16:30 |
IV-038 Charlotte M Thomas
Pharmacokinetic-Pharmacodynamic Modelling of Risankizumab in Plaque Psoriasis Real World Data
Thursday 15:00-16:30 |
IV-039 Anders Thorsted
Item response theory-enabled translation between DAS28 and ACR – Key clinical endpoints within rheumatoid arthritis drug development
Thursday 15:00-16:30 |
IV-040 Paul Thoueille
Pharmacometrics-based analysis of salmeterol and its metabolite α-hydroxysalmeterol in plasma and urine: practical implications for doping control
Thursday 15:00-16:30 |
IV-041 Johannes Tillil
Automated QSP model order reduction combining multiple state-level reduction approaches
Thursday 15:00-16:30 |
IV-042 Elena Tosca
Dealing with stochasticity in precision dosing decision-making processes by fully exploiting PK-PD modelling in Reinforcement Learning algorithms. A practical case-study on Vancomycin continuous infusion in ICU patients
Thursday 15:00-16:30 |
IV-043 Mirjam Trame
FOCE generalized log-likelihood using nlmixr2
Thursday 15:00-16:30 |
IV-044 Van Thuy Truong
Stochastic pharmacodynamics: Drug effects on the time to extinction of a heterogeneous tumour cell population
Thursday 15:00-16:30 |
IV-045 Quan Truong
Underdosing imipenem in patients with renal insufficiency: global clinical data-driven pharmacokinetic/pharmacodynamic study
Thursday 15:00-16:30 |
IV-046 Lufina Tsirizani
Population pharmacokinetics of ritonavir administered to boost lopinavir, atazanavir, or darunavir in children with HIV in Africa.
Thursday 15:00-16:30 |
IV-047 Anastasia Tsyplakova
Population Pharmacokinetics of Valproic Acid, Lamotrigine, and Levetiracetam in the Pediatric Population
Thursday 15:00-16:30 |
IV-048 Diego Valderrama
Integrating Random Effects in Scientific Machine Learning Models for Pharmacokinetic Modeling
Thursday 15:00-16:30 |
IV-049 Debra van Asten
Population pharmacokinetics of ticagrelor and its active metabolite in a real-life hospitalized population
Thursday 15:00-16:30 |
IV-050 Stijn van Beek
Population pharmacokinetic analysis of elafibranor and metabolite GFT1007 to support exposure-response characterization and dose selection in patients with primary biliary cholangitis
Thursday 15:00-16:30 |
IV-051 Marinda van de Kreeke
Quantifying the sensitivity and specificity of CYP450 probe drugs in predicting in vivo enzyme activity under (patho)physiological conditions
Thursday 15:00-16:30 |
IV-052 Stefan van den Berg
Pharmacokinetic model-informed precision dosing of natalizumab in Multiple Sclerosis
Thursday 15:00-16:30 |
IV-053 Tamara van Donge
Middle-out physiologically-based pharmacokinetic modeling to support pediatric dosing recommendation for alectinib, an ALK tyrosine kinase receptor inhibitor
Thursday 15:00-16:30 |
IV-054 Tamara van Donge
Population PK modeling of Vamikibart in aqueous humor, an anti-IL-6 monoclonal antibody, in patients with diabetic and uveitic macular edema
Thursday 15:00-16:30 |
IV-055 Jennie van Dyk
Oral amoxicillin/clavulanate in paediatric patients with severe community acquired pneumonia: a popPK analysis from the PediCAP trial
Thursday 15:00-16:30 |
IV-056 Marloes van Leuken
A population pharmacokinetic model of N,N-dimethyltryptamine administered through continuous intravenous infusion in healthy smokers and non-smokers
Thursday 15:00-16:30 |
IV-057 Martje Van Neste
A semi-systematic review on the maturational physiology in exclusively breastfed infants: Growth – A contribution from the ConcePTION project
Thursday 15:00-16:30 |
IV-058 Martijn van Noort
User-friendly parameter identifiability methods with a workflow to guide model development, using categorical and continuous scales
Thursday 15:00-16:30 |
IV-059 Anne van Rongen
The impact of being born Small for Gestational Age (SGA) on the clearance of vancomycin versus morphine and midazolam
Thursday 15:00-16:30 |
IV-060 Erno van Schaick
Population Pharmacokinetic Modeling of Leriglitazone in Healthy Volunteers and Patients with Neuro-degenerative Disorders – Exploring dosing schedules in children with adrenoleukodystrophy via simulations
Thursday 15:00-16:30 |
IV-061 Daan van Valkengoed
Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?
Thursday 15:00-16:30 |
IV-062 Scott Van Wart
Population Pharmacokinetic (PK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Serum M-Protein in an Ongoing Phase 1/2 Study of Modakafusp Alfa in Patients with Relapsed/Refractory Multiple Myeloma
Thursday 15:00-16:30 |
IV-063 Alberto Vegas
Modelling & simulation of biomarkers during anti-HIV monotherapy treatment
Thursday 15:00-16:30 |
IV-064 Nieves Velez de Mendizabal
A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with chronic hepatitis D
Thursday 15:00-16:30 |
IV-065 Peter Velickovic
Translational pharmacology and dose rationale for imatinib and doramapimod as a host-directed therapy for the treatment of pulmonary tuberculosis
Thursday 15:00-16:30 |
IV-066 Bharadwaj Vemparala
Modeling the influence of antiretroviral treatment initiation time on post-treatment control of HIV infection
Thursday 15:00-16:30 |
IV-067 Esmée Vendel
Belimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis
Thursday 15:00-16:30 |
IV-068 Diego Vera-Yunca
Assessing clinical outcomes of nosocomial pneumonia patients with a pharmacometric multistate model
Thursday 15:00-16:30 |
IV-069 Laura Villain
Considerations for the application of PBPK to optimize drug therapies in special populations: The Open Systems Pharmacology solutions
Thursday 15:00-16:30 |
IV-070 Umberto Villani
Model-based characterisation of host-directed therapeutics against M. tuberculosis in an in vitro experimental model
Thursday 15:00-16:30 |
IV-071 Roberto Visintainer
stormTB: SimulaTOR of a murine Minimal-pbpk model for anti-TB drugs
Thursday 15:00-16:30 |
IV-072 Alina Volkova
Mathematical modeling of autoimmune diseases: a systematic review and analysis for advancing therapeutic development
Thursday 15:00-16:30 |
IV-073 Jannik Vollmer
Combined population PK modelling of cefepime and enmetazobactam to characterize their individual and combined PK from the phase 1 to 3 studies
Thursday 15:00-16:30 |
IV-074 Camille Vong
Multi-Endpoint Item-Response Modelling for Integrating Several Endpoints in Alzheimer’s Disease Drug Trials
Thursday 15:00-16:30 |
IV-075 Thanakorn Vongjarudech
Evaluation of QT Prolongation During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
Thursday 15:00-16:30 |
IV-076 Paul Vrenken
Development of a novel open-source Physiology-Based Biopharmaceutics Modelling (PBBM) framework using the Open System Pharmacology suite
Thursday 15:00-16:30 |
IV-077 My Luong Vuong
Multiple imputation to handle missing covariate data in pharmacometrics modelling
Thursday 15:00-16:30 |
IV-078 Axel Vuorinen
A comparative analysis of Bayesian dose-finding designs incorporating pharmacokinetics information
Thursday 15:00-16:30 |
IV-079 Zhigang Wang
Time-to-event modelling and simulation of the risk of relapse after infusion interval extension of infliximab in patients with inflammatory bowel diseases
Thursday 15:00-16:30 |
IV-080 Shayne Watson
Population PK and PKPD modeling of TBA-7371 in Healthy Adults and Adults with tuberculosis
Thursday 15:00-16:30 |
IV-081 Sebastian Weber
Novel integrated population PD modeling framework to inform decision making during Oncology phase I dose-escalation
Thursday 15:00-16:30 |
IV-082 Franz Weber
Successful validation of a model-informed precision dosing instrument for meropenem in critically ill patients, the DoseCalculator, against NONMEM®
Thursday 15:00-16:30 |
IV-083 Haini Wen
Translational physiologically based pharmacokinetic modeling to predict human pulmonary kinetics after inhalation
Thursday 15:00-16:30 |
IV-084 Dominic Whittaker
Leveraging in vitro data from novel drug candidates to prioritize antibody combinations in autoimmune disease using a QSP model of IBD
Thursday 15:00-16:30 |
IV-085 Ella Widigson
Model-derived PK target profile of ustekinumab therapeutic thresholds in inflammatory bowel diseases to guide precision dosing
Thursday 15:00-16:30 |
IV-086 Marie Wijk
A pragmatic approach to handling data below the lower limit of quantification in complex pharmacokinetic models
Thursday 15:00-16:30 |
IV-087 Mélanie Wilbaux
How to handle population pharmacokinetics modeling in the context of a regulatory submission for a compound already well-characterized in other settings? A case-study with nivolumab in urothelial cancer.
Thursday 15:00-16:30 |
IV-088 Francis Williams Ojara
Population pharmacokinetic characterisation of plasma-to-breast milk transfer of lamivudine and subsequent infant exposure through breast milk
Thursday 15:00-16:30 |
IV-089 Insa Winzenborg
Uncovering Bias in Exposure-Response Relationships: Investigating the Impact of Exposure Calculation for Irregular Dosing Regimens
Thursday 15:00-16:30 |
IV-090 Daniel Wojtyniak
Influential factors on the type I error rate in pharmacometrics models using individual model averaging or standard approach
Thursday 15:00-16:30 |
IV-091 Jan-Georg Wojtyniak
Population Pharmacokinetics of Survodutide in Subjects with Overweight or Obesity with and without Type 2 Diabetes Mellitus Based on Phase I and Phase II Data
Thursday 15:00-16:30 |
IV-092 Yin Cheong Wong
Population pharmacokinetic/pharmacodynamic modeling to evaluate target suppression in patients with advanced solid tumors by ginisortamab, an anti-gremlin-1 monoclonal antibody
Thursday 15:00-16:30 |
IV-093 Jen-Hao (Eric) Wu
Clinical trial design evaluation in pediatric oncology: Phase I dose finding trial design optimization exemplified by brigatinib (ITCC-098)
Thursday 15:00-16:30 |
IV-095 Maria Xiberras
External Validation of a Population Pharmacokinetic Model for Morphine and its Metabolites in Children under 3 Years who Underwent Cardiothoracic Surgery
Thursday 15:00-16:30 |
IV-097 Liang Yang
A combined model meta-analysis of aggregated and individual FEV1 data from randomized COPD trials
Thursday 15:00-16:30 |
IV-098 Eunsol Yang
Translational tool-based phase 2 clinical outcome predictions of the novel diarylquinoline TBAJ-587 for the treatment of tuberculosis, compared to bedaquiline and TBAJ-876
Thursday 15:00-16:30 |
IV-099 Koichiro Yoneyama
Impact of Imbalanced Baseline Responses among Dose Levels in the Exposure-Response Analysis by Nonlinear Mixed-Effect Modeling
Thursday 15:00-16:30 |
IV-100 Huifang You
Machine learning time-to-event analysis for prediction of 2-month culture conversion with phase 2a information in tuberculosis drug development
Thursday 15:00-16:30 |
IV-101 Simone Zannoni
The impact of weekend dosing holidays on the evaluation of the sterilizing efficacy of different 4-drug combinations in a relapsing mouse model of Mycobacterium tuberculosis infection using a logistic Emax model
Thursday 15:00-16:30 |
IV-102 Javier Zarzoso Foj
Individualized dosing regimen optimization of ustekinumab through a population pharmacokinetic-pharmacodynamic model in patients with psoriasis
Thursday 15:00-16:30 |
IV-103 Tatiana Zasedateleva
Local TMDD of large molecules in tissue interstitial space
Thursday 15:00-16:30 |
IV-104 Hinojal Zazo Gómez
Dosing evaluation of ceftazidime/avibactam in intensive care unit patients based on pharmacokinetic-pharmacodinamic (PK/PD) modelling and simulation.
Thursday 15:00-16:30 |
IV-105 Stefan Zeiser
A population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor
Thursday 15:00-16:30 |
IV-106 Mengxu Zhang
Exploring the contribution of brain metabolism in mechanistic understanding of Kp,uu,BBB – A case study for remoxipride
Thursday 15:00-16:30 |
IV-107 Tan Zhang
The impact of drug properties and severity of obesity on renal clearance through glomerular filtration and active tubular secretion
Thursday 15:00-16:30 |
IV-108 Renwei Zhang
Impact of censoring on non-linear effect modeling of aggregate-level survival data
Thursday 15:00-16:30 |
IV-109 Xiao Zhang
Assessment of Sample Size Allocation for A Multi-regional Phase 2 Trial: Comparison of Statistical and Dose-Exposure-Response (D-E-R) Approaches
Thursday 15:00-16:30 |
IV-110 Xiaonan Zhang
Assessing the Effect of Pneumonia on Tigecycline Lung Exposure Using Physiological-Based Pharmacokinetic Modelling
Thursday 15:00-16:30 |
IV-111 Qiaolin Zhao
Population pharmacokinetic analysis for pediatric patients with inflammatory bowel disease receiving infliximab
Thursday 15:00-16:30 |
IV-112 Kirill Zhudenkov
A model-based survival meta-analysis for indirect comparison of immune therapy efficacy in NSCLC
Thursday 15:00-16:30 |
IV-113 Manuela Zimmermann
NLME modelling from a causal inference perspective when the dose-exposure-response relationship is confounded by the treatment regimen
Thursday 15:00-16:30 |
IV-114 Jochen Zisowsky
Target-mediated drug disposition of monoclonal antibody binding to plasma soluble target: some insights from PBPK/PD and popPK/PD approaches
Thursday 15:00-16:30 |
IV-115 Yuanxi Zou
Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis
Thursday 15:00-16:30 |
IV-116 Laura Zwep
Statistical interaction modeling in non-linear mixed effect models: a case study in neonatal pharmacology
Thursday 15:00-16:30 |
